XENE Q2 2020 Earnings — Xenon Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

XENEXenon Pharmaceuticals Inc.

$5B

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$13M

Gross Profit

$13M100.0% margin

Operating Income

-$646,000-4.8% margin

Net Income

-$175,000-1.3% margin

EPS (Diluted)

$-0.01

QoQ Revenue Growth

+89.1%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$11M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$211M

Total Liabilities

$21M

Stockholders' Equity

$189M

Cash & Equivalents

$44M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$13M	$0	—
Gross Profit	$13M	-$8M	+263.1%
Operating Income	-$646,000	-$11M	+93.9%
Net Income	-$175,000	-$10M	+98.3%

Revenue Segments

License And Service

$13M100%